and a 5 year price target of $212.61. These targets indicate potential upsides of 25.25%, and 38.72%, respectively, from its closing price of $153.27 on December 20, 2023. These projections are based on forward multiples of JNJ. The significant potential for the five-year target is driven...
J&J CFO Joseph Wolk on Q2 earnings beat: We're in a very strong position for second half of 2023 Johnson & Johnson on Thursday reported second-quarter revenue and adjusted earnings that topped Wall Street's expectations, and lifted its full-year guidance as sales from the company's medtech ...
Turning to 2025. And as previously guided back at the end of 2023, we expect to deliver operational sales growth of 3%, overcoming headwinds associated with U.S. biosimilar entries for Stelara and the impact of the Part D redesign and continued macroeconomic pressures in China. Perhaps, even ...
Turning to 2025. And as previously guided back at the end of 2023, we expect to deliver operational sales growth of 3%, overcoming headwinds associated with U.S. biosimilar entries for Stelara and the impact of the Part D redesign and continued macroeconomic pressures in China. Perhaps, even ...
Good morning. This is Jessica Moore, Vice President of Investor Relations for Johnson & Johnson. Welcome to our Company’s review of the 2023 third quarter business results and full-year financial outlook. A few logistics before we get into the details. As a reminder, you can find additional...
Annual results Fiscal PeriodDecember 2021 2022 2023 2024 2025 2026 Fiscal Period December 2021 2022 2023 2024 2025 2026 Net salesMillion USD ReleasedForecast Spread 93 77594 304-0.56% 94 94395 017-0.08% 85 15984 7640.47% 88 82188 7650.06% 89 976 93 769 EBITDAMillion USD ReleasedForecast Spre...
Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2023. Previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%. Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get ...
Annual (Values in U.S.thousands) Next 12-202312-202212-202112-202012-2019 Sales85,159,00079,990,00078,740,00082,584,00082,059,000 Cost of Goods26,553,00024,596,00023,402,00028,427,00027,556,000 Gross Profit58,606,00055,394,00055,338,00054,157,00054,503,000 ...
Data YoY Growth YoY Growth % Timeframe Annual Quarterly Period End Date TTM 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 Period Length 12 Months 12 Months 12 Months Upgrade your FINVIZ experience Join thousands of traders who make more informed decisions...
但实际上,过去五年,FDA批准的新药仍以小分子化学药为主,2019-2023年占比分别为65%、62%、56%、46%、55%。小分子药物以其独特的穿透力和便捷性,依旧在大分子药物的快速发展浪潮中稳居半壁江山。特别是在一些跨国药企的核心管线中,小分子药物,尤其是近年来异军突起的长效注射小分子,正展现出前所未有的活力与潜力...